Novartis launches DTC campaign for Entresto
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
DTC
When it comes to professional ads, print makes its comeback
Following print’s best year since 2011, it’s time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.
Drugmakers go to DTC to promote IBS drugs
The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.
MannKind reworks commercial strategy for Afrezza
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Larry Dobrow on the Worst DTC ads of 2015
One side effect (pun super-deliberately intended) of prompting pharma creatives to come up with new go-to visuals is that, well, not every idea or execution is a keeper.
2015 DTC spending: All the data in one place
Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.
A ranking of 2015’s DTC Ads
Great DTC pharma advertising during the last year or so has been “sparse,” says SSCG Media Group president Debbie Renner. Still, here are her top 10 picks for 2015.
DTC Report 2016: Gut Check
DTC is facing a new test from physicians and politicians. Here’s why critics fear a deluge, and how they’re pushing back.
Another physician group raises concerns about DTC
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
Five things for pharma marketers to know: Monday, March 28, 2016
Experts say DTC spending is a waste; Alder BioPharma’s migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences
